MCS-222

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameMCS-222
Drug Alias NameCovid-19 therapy (Medsenic)MCS-222
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytokine receptors modulators
TargetsCytokine receptors
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedsenic
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedsenic
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A
Related LinksN/A